Figure 7
Altered expression of VEGFR-3 on blood vessels in IL-12-expressing tumours. (A) Whole mount preparations of B16 (top row) and B16/IL-12 (bottom row) tumours were stained with biotin-conjugated anti-VEGFR-3 and PE–streptavidin and viewed for green fluorescence (left images) or red fluorescence (right images). All images are of the same magnification; the bar represents 100 μm. (B) Cryrostat sections (4 μm) were prepared from B16 (top row) and B16/IL-12 (bottom row) tumours and stained with PE-anti-CD31 and with biotin-conjugated anti-VEGFR-3 and APC–streptavidin and viewed for PE fluorescence (left images) or APC fluorescence (right images). All images are of the same magnification; the bar represents 100 μm.
